Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Dec 2019
Historique:
pmc-release: 01 12 2019
pubmed: 7 11 2019
medline: 17 4 2020
entrez: 8 11 2019
Statut: ppublish

Résumé

The Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). SLE patients in LLDAS for more than half of the observation time have about a 50% lower risk of new organ damage and have reduced mortality. We identified predictors of being in LLDAS ≥50% of the observation time. A total of 2228 SLE patients who had at least three clinical visits were included. Percentage of time in LLDAS was calculated based on the proportion of days under observation. LLDAS-50 was defined as being in LLDAS for ≥50% of the observation time. We used the stepwise selection procedure in logistic regression to identify predictors of LLDAS-50. A total of 1169 (52.5%) SLE patients, but only 37.6% of African Americans, achieved LLDAS-50. In the multivariable model, African American ethnicity, hypocomplementemia, serositis, renal activity, arthritis, anti-RNP, anti-dsDNA, vasculitis, malar rash, discoid rash, thrombocytopenia, and immunosuppressive use were negative predictors of LLDAS-50. Older age at diagnosis, longer disease duration, higher education level, and greater percentage of time taking hydroxychloroquine remained positive predictors of LLDAS-50. In this large cohort, only 52.5% achieved LLDAS-50. This proportion was even less in African Americans. A higher percentage of time taking hydroxychloroquine was a modifiable positive predictor of LLDAS-50. Anti-RNP, anti-dsDNA, and low complement were negatively associated with LLDAS-50. Our findings further emphasize the importance of inclusion of African Americans in clinical trials and hydroxychloroquine adherence in both clinical practice and clinical trials.

Identifiants

pubmed: 31694446
doi: 10.1177/0961203319886028
pmc: PMC6872940
mid: NIHMS1541208
doi:

Substances chimiques

Antibodies, Antinuclear 0
Hydroxychloroquine 4QWG6N8QKH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1648-1655

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR043727
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States

Références

Ann Rheum Dis. 2018 Jan;77(1):104-110
pubmed: 28970217
Arthritis Rheumatol. 2018 Nov;70(11):1790-1795
pubmed: 29806142
Medicine (Baltimore). 2006 May;85(3):147-56
pubmed: 16721257
J Rheumatol. 2015 Nov;42(11):2092-7
pubmed: 26428205
Arthritis Rheum. 2013 Mar;65(3):753-63
pubmed: 23203603
Ann Rheum Dis. 2006 Nov;65(11):1500-5
pubmed: 16627544
Medicine (Baltimore). 2010 Jan;89(1):62-7
pubmed: 20075706
Lancet. 2019 Feb 2;393(10170):402-403
pubmed: 30712893
Lupus Sci Med. 2017 May 22;4(1):e000200
pubmed: 29177060
Ann Rheum Dis. 2019 May;78(5):629-633
pubmed: 30679152
Arthritis Care Res (Hoboken). 2019 Mar 1;:null
pubmed: 30821926
Arthritis Res Ther. 2016 Nov 9;18(1):260
pubmed: 27829463
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Arthritis Rheum. 2013 Aug;65(8):2143-53
pubmed: 23754628
N Engl J Med. 2005 Dec 15;353(24):2550-8
pubmed: 16354891
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
Arch Intern Med. 1990 Apr;150(4):849-53
pubmed: 2327845
Arthritis Rheum. 1998 Jul;41(7):1173-80
pubmed: 9663472
Rheumatology (Oxford). 2004 Aug;43(8):1039-44
pubmed: 15161983
Lupus Sci Med. 2018 Nov 2;5(1):e000287
pubmed: 30538818
Rheum Dis Clin North Am. 2000 May;26(2):199-213, v
pubmed: 10768209
Ann Rheum Dis. 2007 Sep;66(9):1168-72
pubmed: 17389655
Nat Rev Rheumatol. 2016 Oct;12(10):605-20
pubmed: 27558659
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Arthritis Rheum. 2005 May;52(5):1473-80
pubmed: 15880829
Ann Rheum Dis. 2016 Dec;75(12):e78
pubmed: 27797752
Arthritis Res Ther. 2017 Mar 20;19(1):62
pubmed: 28320433
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Rheumatology (Oxford). 2018 Feb 1;57(2):337-344
pubmed: 29121273
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
J Rheumatol. 1992 Jan;19(1):53-9
pubmed: 1556700
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Lupus Sci Med. 2018 Feb 27;5(1):e000234
pubmed: 29531772
Lupus. 2002;11(3):152-60
pubmed: 12004788
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Lupus. 2002;11(2):95-101
pubmed: 11958584
Arthritis Rheum. 1999 Dec;42(12):2682-8
pubmed: 10616018
Lupus. 2006;15(9):577-83
pubmed: 17080912
Lupus. 2018 Apr;27(5):722-727
pubmed: 29087260
Lupus. 2010 May;19(6):727-33
pubmed: 20118158
Arthritis Rheum. 1990 May;33(5):634-43
pubmed: 2346519
Lupus. 1999;8(3):197-209
pubmed: 10342712
Rheumatology (Oxford). 2017 Jan;56(1):121-128
pubmed: 27803306
Immunol Rev. 2010 Jan;233(1):126-45
pubmed: 20192997
N Engl J Med. 1991 Jan 17;324(3):150-4
pubmed: 1984192
Ann Rheum Dis. 2018 May;77(5):706-713
pubmed: 29420200
Lupus. 2002;11(3):161-7
pubmed: 11999880

Auteurs

H Babaoglu (H)

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey.

J Li (J)

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

D Goldman (D)

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

L S Magder (LS)

Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, USA.

M Petri (M)

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH